Published in J Clin Invest on February 01, 1997
Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer (2009) 3.45
p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med (1998) 2.91
Apoptosis: a mechanism of acute and chronic liver injury. Gut (2005) 2.33
TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J (2005) 1.90
Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest (1998) 1.79
Activation-dependent transcriptional regulation of the human Fas promoter requires NF-kappaB p50-p65 recruitment. Mol Cell Biol (1999) 1.45
Hepatic IGFBP1 is a prosurvival factor that binds to BAK, protects the liver from apoptosis, and antagonizes the proapoptotic actions of p53 at mitochondria. Genes Dev (2007) 1.37
Recent advances in p53 research and cancer treatment. J Biomed Biotechnol (2011) 1.31
CDIP, a novel pro-apoptotic gene, regulates TNFalpha-mediated apoptosis in a p53-dependent manner. EMBO J (2007) 1.25
Zerumbone induced apoptosis in liver cancer cells via modulation of Bax/Bcl-2 ratio. Cancer Cell Int (2007) 1.25
Oxidized LDL activates fas-mediated endothelial cell apoptosis. J Clin Invest (1998) 1.23
Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin Exp Immunol (2002) 1.21
p53 Involvement in the control of murine hair follicle regression. Am J Pathol (2001) 1.19
Roles of Fas and Fas ligand during mammary gland remodeling. J Clin Invest (2000) 1.18
Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells. Hum Gene Ther (2008) 1.17
Differential regulation and ATP requirement for caspase-8 and caspase-3 activation during CD95- and anticancer drug-induced apoptosis. J Exp Med (1998) 1.16
Ischemia/Reperfusion injury in liver surgery and transplantation: pathophysiology. HPB Surg (2012) 1.12
Targeting cell death in tumors by activating caspases. Curr Cancer Drug Targets (2008) 1.10
The expression of Fas Ligand by macrophages and its upregulation by human immunodeficiency virus infection. J Clin Invest (1998) 1.09
Transcription abnormalities potentiate apoptosis of normal human fibroblasts. Mol Med (1997) 1.08
The Fas death signaling pathway connecting reactive oxygen species generation and FLICE inhibitory protein down-regulation. J Immunol (2008) 1.08
Nitric oxide and redox regulation in the liver: Part I. General considerations and redox biology in hepatitis. J Surg Res (2009) 1.03
The Fas counterattack: a molecular mechanism of tumor immune privilege. Mol Med (1997) 0.99
T cell-tumor cell: a fatal interaction? Cancer Immunol Immunother (1998) 0.97
Restraint stress induces lymphocyte reduction through p53 and PI3K/NF-kappaB pathways. J Neuroimmunol (2008) 0.97
A critical role for Fas ligand in the active suppression of systemic immune responses by ultraviolet radiation. J Exp Med (1999) 0.96
Royal jelly modulates oxidative stress and apoptosis in liver and kidneys of rats treated with cisplatin. Oxid Med Cell Longev (2011) 0.96
A novel AP-1 element in the CD95 ligand promoter is required for induction of apoptosis in hepatocellular carcinoma cells upon treatment with anticancer drugs. Mol Cell Biol (2000) 0.96
Yes-associated protein (YAP) increases chemosensitivity of hepatocellular carcinoma cells by modulation of p53. Cancer Biol Ther (2013) 0.95
ST6Gal-I sialyltransferase confers cisplatin resistance in ovarian tumor cells. J Ovarian Res (2013) 0.95
Autophagy inhibits oxidative stress and tumor suppressors to exert its dual effect on hepatocarcinogenesis. Cell Death Differ (2014) 0.95
Differential role of transcription-coupled repair in UVB-induced G2 arrest and apoptosis in mouse epidermis. Proc Natl Acad Sci U S A (2000) 0.93
Colchicine protects mice from the lethal effect of an agonistic anti-Fas antibody. J Clin Invest (2000) 0.92
Cellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor Radiosensitization. Int J Mol Sci (2016) 0.91
IGFBP-3 mediates p53-induced apoptosis during serum starvation. Int J Oncol (2002) 0.89
Synergistic inhibition of autophagy and neddylation pathways as a novel therapeutic approach for targeting liver cancer. Oncotarget (2015) 0.89
Involvement of ER stress in apoptosis induced by sialic acid-binding lectin (leczyme) from bullfrog eggs. Int J Oncol (2013) 0.89
Gallium compound GaQ(3) -induced Ca(2+) signalling triggers p53-dependent and -independent apoptosis in cancer cells. Br J Pharmacol (2012) 0.88
High cell surface death receptor expression determines type I versus type II signaling. J Biol Chem (2011) 0.88
Nucleolin inhibits Fas ligand binding and suppresses Fas-mediated apoptosis in vivo via a surface nucleolin-Fas complex. Blood (2013) 0.88
Promoter region methylation does not account for the frequent loss of expression of the Fas gene in colorectal carcinoma. Br J Cancer (2000) 0.86
T lymphocyte mediated lysis of mitomycin C treated Tenon's capsule fibroblasts. Br J Ophthalmol (2004) 0.86
Camptothecin sensitizes androgen-independent prostate cancer cells to anti-Fas-induced apoptosis. Br J Cancer (1999) 0.86
CD95 is part of a let-7/p53/miR-34 regulatory network. PLoS One (2012) 0.85
Beta-irradiation used for systemic radioimmunotherapy induces apoptosis and activates apoptosis pathways in leukaemia cells. Eur J Nucl Med Mol Imaging (2003) 0.85
Melatonin induces transcriptional regulation of Bim by FoxO3a in HepG2 cells. Br J Cancer (2012) 0.85
Mitomycin C induces bystander killing in homogeneous and heterogeneous hepatoma cellular models. Mol Cancer (2009) 0.85
Butyric acid-induced T-cell apoptosis is mediated by caspase-8 and -9 activation in a Fas-independent manner. Clin Diagn Lab Immunol (2001) 0.85
Hepatitis C virus NS2 protein inhibits DNA damage pathway by sequestering p53 to the cytoplasm. PLoS One (2013) 0.85
Solanum lyratum Extracts Induce Extrinsic and Intrinsic Pathways of Apoptosis in WEHI-3 Murine Leukemia Cells and Inhibit Allograft Tumor. Evid Based Complement Alternat Med (2012) 0.83
Apoptosis is induced in both drug-sensitive and multidrug-resistant hepatoma cells by somatostatin analogue TT-232. Br J Cancer (1999) 0.83
Killing of p53-deficient hepatoma cells by parvovirus H-1 and chemotherapeutics requires promyelocytic leukemia protein. World J Gastroenterol (2008) 0.82
Indomethacin-induced activation of the death receptor-mediated apoptosis pathway circumvents acquired doxorubicin resistance in SCLC cells. Br J Cancer (2005) 0.82
Relationship between therapeutic efficacy of arterial infusion chemotherapy and expression of P-glycoprotein and p53 protein in advanced hepatocellular carcinoma. World J Gastroenterol (2006) 0.82
The effects of fucodian on senescence are controlled by the p16INK4a-pRb and p14Arf-p53 pathways in hepatocellular carcinoma and hepatic cell lines. Int J Oncol (2014) 0.82
Deficient activation of CD95 (APO-1/Fas)-mediated apoptosis: a potential factor of multidrug resistance in human renal cell carcinoma. Br J Cancer (2000) 0.82
Adoptive transfer of human papillomavirus E7-specific CTL enhances tumor chemoresponse through the perforin/granzyme-mediated pathway. Mol Ther (2009) 0.82
Overexpression of HBxAg in hepatocellular carcinoma and its relationship with Fas/FasL system. World J Gastroenterol (2003) 0.82
TRAIL receptor signaling regulation of chemosensitivity in vivo but not in vitro. PLoS One (2011) 0.82
Regulation of cell death receptor S-nitrosylation and apoptotic signaling by Sorafenib in hepatoblastoma cells. Redox Biol (2015) 0.81
Depletion of hepatic glutathione prevents death receptor-dependent apoptotic and necrotic liver injury in mice. Am J Pathol (2000) 0.81
Gemcitabine sensitizes lung cancer cells to Fas/FasL system-mediated killing. Immunology (2014) 0.81
Roles of proinflammatory cytokines and the Fas/Fas ligand interaction in the pathogenesis of inflammatory myopathies. Immunology (2008) 0.81
Ceramide Synthase 6 Is a Novel Target of Methotrexate Mediating Its Antiproliferative Effect in a p53-Dependent Manner. PLoS One (2016) 0.81
Combination of hepatocyte specific delivery and transformation dependent expression of shRNA inducing transcriptional gene silencing of c-Myc promoter in hepatocellular carcinoma cells. BMC Cancer (2014) 0.80
Up-regulation of Fas reverses cisplatin resistance of human small cell lung cancer cells. J Exp Clin Cancer Res (2010) 0.80
Pigment epithelial-derived factor (PEDF)-triggered lung cancer cell apoptosis relies on p53 protein-driven Fas ligand (Fas-L) up-regulation and Fas protein cell surface translocation. J Biol Chem (2014) 0.80
Pathophysiological Significance of Hepatic Apoptosis. ISRN Hepatol (2012) 0.79
PMLRARα binds to Fas and suppresses Fas-mediated apoptosis through recruiting c-FLIP in vivo. Blood (2011) 0.79
Apoptosis of haematopoietic cells upon thymidylate synthase inhibition is independent of p53 accumulation and CD95-CD95 ligand interaction. Biochem J (2001) 0.79
Distinctive pharmacological differences between liver cancer cell lines HepG2 and Hep3B. Cytotechnology (2014) 0.78
Clofibrate treatment in pigs: effects on parameters critical with respect to peroxisome proliferator-induced hepatocarcinogenesis in rodents. BMC Pharmacol (2007) 0.78
Fractionated gamma-irradiation renders tumour cells more responsive to apoptotic signals through CD95. Br J Cancer (1999) 0.78
The peptide derived from the Ig-like domain of human herpesvirus 8 K1 protein induces death in hematological cancer cells. J Exp Clin Cancer Res (2012) 0.78
Strategy to enhance efficacy of doxorubicin in solid tumor cells by methyl-β-cyclodextrin: Involvement of p53 and Fas receptor ligand complex. Sci Rep (2015) 0.78
Effect of methotrexate on cerebellar development in infant rats. J Vet Med Sci (2015) 0.78
DNA damage induces down-regulation of Prp19 via impairing Prp19 stability in hepatocellular carcinoma cells. PLoS One (2014) 0.77
Serum starvation induces DRAM expression in liver cancer cells via histone modifications within its promoter locus. PLoS One (2012) 0.77
Characterisation of molecular events following cisplatin treatment of two curable ovarian cancer models: contrasting role for p53 induction and apoptosis in vivo. Br J Cancer (2004) 0.77
Complex changes in the apoptotic and cell differentiation programs during initiation of the hair follicle response to chemotherapy. J Invest Dermatol (2014) 0.77
Effect of methotrexate on neuroepithelium in the rat fetal brain. J Vet Med Sci (2013) 0.77
Time course changes of anti- and pro-apoptotic proteins in apigenin-induced genotoxicity. Chin Med (2013) 0.77
Temperature sensitivity of human wild-type and mutant p53 proteins expressed in vivo. Br J Cancer (1998) 0.77
Chloroquine inhibits hepatocellular carcinoma cell growth in vitro and in vivo. Oncol Rep (2015) 0.75
Vitamin C enhances anticancer activity in methotrexate‑treated Hep3B hepatocellular carcinoma cells. Oncol Rep (2014) 0.75
A Positive TGF-β/c-KIT Feedback Loop Drives Tumor Progression in Advanced Primary Liver Cancer. Neoplasia (2016) 0.75
Increased expression but not sensitivity to Fas/CD95 in glioblastoma cells depleted of mitochondrial DNA. Exp Ther Med (2010) 0.75
Acrolein enhances epigenetic modifications, FasL expression and hepatocyte toxicity induced by anti-HIV drug Zidovudine. Toxicol In Vitro (2016) 0.75
Effect of methotrexate exposure at late gestation on development of telencephalon in rat fetal brain. J Vet Med Sci (2015) 0.75
The effects of chemotherapeutics on cellular metabolism and consequent immune recognition. J Immune Based Ther Vaccines (2004) 0.75
Effect of methotrexate exposure at middle gestation on the inner plate of the ocular cup and lens in the rat fetus. J Toxicol Pathol (2016) 0.75
Induction of Fas (CD95/APO-1) ligand is essential for p53-dependent apoptosis in an in vitro renal carcinoma model system. J Cancer Res Clin Oncol (2007) 0.75
Signal transduction and mechanisms of cell death. Sixth colloquium on cellular signal transduction, 17 January 1997, Heidelberg, Germany. J Cancer Res Clin Oncol (1997) 0.75
A review on the effects of current chemotherapy drugs and natural agents in treating non-small cell lung cancer. Biomedicine (Taipei) (2017) 0.75
Paclitaxel (Taxol)-induced apoptosis in human epithelioid sarcoma cell lines is enhanced by upregulation of CD95 ligand (FasL/Apo-1L). J Cancer Res Clin Oncol (2007) 0.75
WAF1, a potential mediator of p53 tumor suppression. Cell (1993) 38.72
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul (1984) 35.22
Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol (1992) 34.17
A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell (1992) 19.87
A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods (1991) 16.64
Participation of p53 protein in the cellular response to DNA damage. Cancer Res (1991) 16.00
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell (1995) 14.90
p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (1993) 13.46
FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death--inducing signaling complex. Cell (1996) 12.07
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell (1993) 12.02
The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell (1991) 10.96
Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature (1993) 10.72
The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell (1994) 9.25
Lethal effect of the anti-Fas antibody in mice. Nature (1993) 9.20
Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell (1993) 9.06
Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci U S A (1992) 8.87
Autocrine T-cell suicide mediated by APO-1/(Fas/CD95) Nature (1995) 8.23
mdm2 expression is induced by wild type p53 activity. EMBO J (1993) 8.01
Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science (1989) 7.76
Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J (1995) 7.60
Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science (1994) 7.34
Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene (1994) 7.24
Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature (1979) 6.76
Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science (1994) 6.11
Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature (1994) 5.58
Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J (1995) 4.68
Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med (1996) 4.51
Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature (1995) 4.20
Apoptosis in cancer therapy: crossing the threshold. Cell (1994) 4.18
Gene induction by gamma-irradiation leads to DNA fragmentation in lymphocytes. J Immunol (1987) 3.89
Requirement of an ICE/CED-3 protease for Fas/APO-1-mediated apoptosis. Nature (1995) 3.59
Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene (1993) 3.43
A license to kill. Cell (1996) 3.37
Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med (1995) 3.20
The CTL's kiss of death. Cell (1995) 2.80
Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med (1996) 2.65
Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys (1979) 2.63
Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol (1995) 2.62
Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med (1996) 2.51
Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice. Nat Med (1996) 2.26
Fas antigen and p55 TNF receptor signal apoptosis through distinct pathways. J Immunol (1994) 2.06
Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens. J Immunol (1992) 1.94
Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res (1996) 1.93
Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood (1993) 1.90
Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res (1994) 1.90
Regulation of apoptosis in the immune system. Curr Opin Immunol (1994) 1.89
Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells. Oncogene (1995) 1.87
p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis (1993) 1.84
Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat Genet (1994) 1.76
Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med (1986) 1.67
p53 activity and chemotherapy. Nat Med (1996) 1.53
Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc Natl Acad Sci U S A (1994) 1.53
p53 tumor suppressor gene: from the basic research laboratory to the clinic--an abridged historical perspective. Carcinogenesis (1996) 1.46
Shifting the cancer paradigm: must we kill to cure? J Clin Oncol (1995) 1.44
Phenotypical stability of a human hepatoma cell line, HuH-7, in long-term culture with chemically defined medium. Gan (1984) 1.40
Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. Blood (1993) 1.20
p53 and chemosensitivity. Nat Med (1996) 1.06
p53 overexpression is frequent in European hepatocellular carcinoma and largely independent of the codon 249 hot spot mutation. Oncogene (1994) 1.06
A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol (1989) 1.04
Assignment of the human Fas antigen gene (Fas) to 10q24.1. Genomics (1992) 1.03
CD95 (APO-1/Fas)-associating signalling proteins. Cell Death Differ (1996) 1.02
APO-1 (CD95)-dependent and -independent antigen receptor-induced apoptosis in human T and B cell lines. Int Immunol (1995) 1.02
Hepatocarcinoma-specific mutant p53-249ser induces mitotic activity but has no effect on transforming growth factor beta 1-mediated apoptosis. Cancer Res (1994) 1.02
Pharmacokinetics of cis-diamminedichloroplatinum (II) given as low-dose and high-dose infusions. J Surg Oncol (1996) 1.00
The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the alpha-fetoprotein status. Hepatology (1993) 0.93
Bleomycin clinical pharmacology by radioimmunoassay. Cancer Chemother Pharmacol (1982) 0.92
Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion. Cancer Chemother Pharmacol (1993) 0.88
Involvement of a putative protein-tyrosine phosphatase and I kappa B-alpha serine phosphorylation in nuclear factor kappa B activation by tumor necrosis factor. J Biol Chem (1995) 0.84
FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death--inducing signaling complex. Cell (1996) 12.07
Two CD95 (APO-1/Fas) signaling pathways. EMBO J (1998) 10.42
Autocrine T-cell suicide mediated by APO-1/(Fas/CD95) Nature (1995) 8.23
Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science (1989) 7.76
Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J (1995) 7.60
Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976. J Biol Chem (1993) 7.16
Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature (1997) 6.23
Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion? Nat Med (1996) 5.09
Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature (1995) 4.95
The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ (2003) 4.72
Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J (1995) 4.68
Increased expression of Ia antigens on resting B cells: an additional role for B-cell growth factor. Proc Natl Acad Sci U S A (1984) 4.62
FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J (1997) 4.56
T cell-derived B cell differentiation factor(s). Effect on the isotype switch of murine B cells. J Exp Med (1982) 4.51
Serological, biochemical, and functional identity of B cell-stimulatory factor 1 and B cell differentiation factor for IgG1. J Exp Med (1985) 4.47
The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J Exp Med (2002) 4.47
T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor. J Exp Med (1992) 4.31
Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature (1995) 4.20
Long-term survival in patients with hereditary hemochromatosis. Gastroenterology (1996) 4.00
Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med (1985) 3.73
FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J Biol Chem (1996) 3.72
Requirement of an ICE/CED-3 protease for Fas/APO-1-mediated apoptosis. Nature (1995) 3.59
The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem (1999) 3.32
Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med (1995) 3.20
Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest (1993) 3.13
FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity (2000) 2.99
Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J Biol Chem (2001) 2.94
p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med (1998) 2.91
Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol (1990) 2.72
Mathematical modeling reveals threshold mechanism in CD95-induced apoptosis. J Cell Biol (2004) 2.70
Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med (1996) 2.65
Clinical presentation, diagnosis and long-term outcome of Wilson's disease: a cohort study. Gut (2006) 2.53
Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J Biol Chem (1999) 2.52
Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med (1997) 2.46
Activation interferes with the APO-1 pathway in mature human T cells. Int Immunol (1993) 2.45
Macrolide-induced Churg-Strauss syndrome in a patient with atopy. Lancet (1997) 2.42
B-cell growth factor (B-cell growth factor I or B-cell-stimulating factor, provisional 1) is a differentiation factor for resting B cells and may not induce cell growth. Proc Natl Acad Sci U S A (1985) 2.41
FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol (2001) 2.39
Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res (1997) 2.32
In vivo imaging of colitis and colon cancer development in mice using high resolution chromoendoscopy. Gut (2005) 2.30
FLICE is predominantly expressed as two functionally active isoforms, caspase-8/a and caspase-8/b. J Biol Chem (1997) 2.29
Diversity of Helicobacter pylori vacA and cagA genes and relationship to VacA and CagA protein expression, cytotoxin production, and associated diseases. J Clin Microbiol (1998) 2.26
In vivo molecular imaging with cetuximab, an anti-EGFR antibody, for prediction of response in xenograft models of human colorectal cancer. Endoscopy (2013) 2.25
TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ (2005) 2.25
Targeting the function of mature dendritic cells by human cytomegalovirus: a multilayered viral defense strategy. Immunity (2001) 2.24
Perforation of the esophagus after dilation treatment for dysphagia in a patient with eosinophilic esophagitis. Endoscopy (2006) 2.24
Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis, independent of dominant stenosis. Aliment Pharmacol Ther (2014) 2.15
Risk of infection with Helicobacter pylori and hepatitis A virus in different groups of hospital workers. Am J Gastroenterol (1997) 2.09
Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke. Cell Death Differ (2001) 2.08
Divergent signalling via APO-1/Fas and the TNF receptor, two homologous molecules involved in physiological cell death. EMBO J (1994) 2.05
Specific binding of alloantigens to T cells activated in the mixed lymphocyte reaction. J Exp Med (1976) 2.04
Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Arthritis Rheum (1995) 2.03
High definition colonoscopy combined with i-Scan is superior in the detection of colorectal neoplasias compared with standard video colonoscopy: a prospective randomized controlled trial. Endoscopy (2010) 2.01
HIV-1 Tat potentiates TNF-induced NF-kappa B activation and cytotoxicity by altering the cellular redox state. EMBO J (1995) 2.01
Differences between CD95 type I and II cells detected with the CD95 ligand. Cell Death Differ (1999) 1.99
Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis. Curr Opin Immunol (1998) 1.96
Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens. J Immunol (1992) 1.94
The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res (2000) 1.91
Different pathways mediate virus inducibility of the human IFN-alpha 1 and IFN-beta genes. Cell (1990) 1.91
Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int J Cancer (1994) 1.87
Involvement of the CD95 (APO-1/Fas) receptor and ligand system in Helicobacter pylori-induced gastric epithelial apoptosis. J Clin Invest (1998) 1.86
Regulation of CD95/Fas signaling at the DISC. Cell Death Differ (2011) 1.86
In vivo diagnosis of collagenous colitis by confocal endomicroscopy. Gut (2006) 1.82
B cell-stimulatory factor 1 (BSF-1) promotes growth of helper T cell lines. J Exp Med (1986) 1.82
CD95 (APO-1/Fas)-mediated apoptosis in colon epithelial cells: a possible role in ulcerative colitis. Gastroenterology (1997) 1.81
IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle (2005) 1.79
Is stenting necessary after balloon dilation of post-transplantation biliary strictures? Results of a prospective comparative study. Endoscopy (2008) 1.76
Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4. Cell Death Differ (2008) 1.76
Cell nucleus and DNA fragmentation are not required for apoptosis. J Cell Biol (1994) 1.75
Interferon gamma and lymphotoxin or tumor necrosis factor act synergistically to induce macrophage killing of tumor cells and schistosomula of Schistosoma mansoni. J Exp Med (1987) 1.75
Infectious hepatitis B virus variant defective in pre-S2 protein expression in a chronic carrier. Virology (1993) 1.75
[German S3-guideline "Diagnosis and treatment of esophagogastric cancer"]. Z Gastroenterol (2011) 1.74
Most influenza A virus-specific memory cytotoxic T lymphocytes react with antigenic epitopes associated with internal virus determinants. J Exp Med (1984) 1.71
Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene (2000) 1.69
Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ (2004) 1.62
Survival and recurrence after liver transplantation versus liver resection for hepatocellular carcinoma: a retrospective analysis. Ann Surg (1998) 1.61